Search

Displaying results 4261 - 4270 of 8578 in total
  1. Drug

    Casdatifan

    go.drugbank.com/drugs/DB21701
    Investigational

    Casdatifan has a monoisotopic molecular weight of 439.09 Da. … Casdatifan is under investigation in clinical trial NCT07000149 (A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC)

  2. Drug

    Acellular nerve allograft

    go.drugbank.com/drugs/DB30293
    ApprovedInvestigational

    Approved by the FDA under a Biologics License Application (BLA) as an acellular nerve scaffold for the treatment of adult and pediatric patients (aged ≥1 month) with sensory, mixed, and motor peripheral

  3. Drug

    EPC2407

    go.drugbank.com/drugs/DB05189
    Investigational

    EPC2407 is a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas. It is intended for the treatment of advanced cancer patients with solid tumors that...

  4. Drug

    Desoximetasone

    go.drugbank.com/drugs/DB00547
    Approved

    A topical anti-inflammatory glucocorticoid used in dermatoses, skin allergies, psoriasis, etc.

    Products: BIOQUIFLOX ® TABLETA RECUBIERTA 500MG.
  5. Drug

    Glutamic acid

    go.drugbank.com/drugs/DB00142
    ApprovedInvestigationalNutraceutical

    A peptide that is a homopolymer of glutamic acid.

  6. Drug

    Demecarium

    go.drugbank.com/drugs/DB00944
    Approved

    Demecarium is an indirect-acting parasympathomimetic agent that is used to treat glaucoma. It is a cholinesterase inhibitor or an anticholinesterase. Cholinesterase inhibitors prolong the effect of acetylcholine, which is released at the...

  7. Drug

    Boldenone

    go.drugbank.com/drugs/DB01541
    ExperimentalIllicitVet approved

    Boldenone is an anabolic steroid developed for veterinary use, mostly for treatment of horses. It is not indicated for use in humans in the US and is only available through veterinary clinics.

  8. Drug

    Omega-6 fatty acids

    go.drugbank.com/drugs/DB13168
    InvestigationalNutraceutical

    They are a family of fatty acid molecules that act as precursors to potent lipid mediator signalling molecules with either pro-inflammatory and anti-inflammatory effects. … Cells involved in the inflammatory response are typically rich in the n-6 fatty acid arachidonic acid, as generally, eicosanoids derived from n-6 PUFA are pro-inflammatory.

  9. Drug

    Beremagene geperpavec

    go.drugbank.com/drugs/DB17831
    ApprovedInvestigational

    Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB).

  10. Drug

    Pancrelipase amylase

    go.drugbank.com/drugs/DB11065
    ApprovedInvestigational

    [L2512] The pancrelipase mixture, including pancrelipase amylase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]